Jennifer Akosa, PharmD/MBA Candidate 2020, and Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP

Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) is indicated for treating adults with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2–based regimens in the setting of metastasis.